Struggling with a Crohn’s flare?
You have options.

Join local clinical trials for people with Crohn’s.

Those who qualify may receive*:

  • Compensation for travel
  • No-cost study medication

If you are eligible and choose to participate, you may receive clinical trial related care and medical advice.

Ready to get started? Click Here.

Crohn’s disease is an autoimmune disease that can severely damage parts of the entire digestive tract.

  • Symptoms of Crohn’s vary from one person to the next and may include frequent diarrhea, abdominal pain, fatigue, reduced appetite, unexplained weight loss or fever.
  • People with Crohn’s disease sometimes experience a period of worsening of symptoms, known as “active” disease or a flare.
  • Flares can interfere with daily activities such as work, family and leisure, causing people to stay at home or only go to places where bathrooms are nearby.

While some people find their symptoms are managed by medications, many others do not find relief. Better treatment options are needed for people who suffer with Crohn’s disease. Right now, local doctors are looking for people who have worsening Crohn’s symptoms to participate in clinical trials.

You may qualify for local clinical trials. But don’t delay — space is limited!

*In a clinical trial, the participants may receive investigational product or may receive an inactive substance, or placebo, depending on the design of the clinical trial. Participants receive clinical trial related care and medical advice for the duration of the trial. Reasonable compensation will be made for travel and the length of the trial may vary.

Ready to get started?

Click Here.

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

AcurianHealth

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.